Related Experiment Video

Updated: Mar 30, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes

Ichiro Kishimoto1, Hisashi Makino1, Yoko Ohata1

  • 1Department of Endocrinology and Metabolism , National Cerebral and Cardiovascular Center , Osaka , Japan.

BMJ Open Diabetes Research & Care
|November 14, 2015
PubMed

Insights

Moderate-intensity statins significantly reduce heart failure (HF) risk in type 2 diabetes patients compared to low-intensity or no statin use. This benefit is independent of LDL cholesterol and coronary artery disease events.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Heart failure (HF) is a significant complication in patients with type 2 diabetes.
  • Statins are widely used to manage cardiovascular risk factors in diabetic patients.
  • The impact of statin intensity on HF incidence in diabetes requires further clarification.

Purpose of the Study:

  • To investigate the association between different statin intensities and the incidence of heart failure in individuals with type 2 diabetes.
  • To determine if statin intensity influences HF risk independently of other cardiovascular risk factors.

Main Methods:

  • Retrospective cohort study of 600 patients with type 2 diabetes.
  • Patients were stratified into three groups based on baseline statin use: moderate-intensity, low-intensity, or no statin.
  • Cox regression analysis was employed to assess the association between statin category and HF hospitalization, adjusting for multiple covariates.

Main Results:

  • Over a median 6-year follow-up, 17.7% of patients were hospitalized for HF.
  • Moderate-intensity statin use was significantly associated with a lower risk of HF hospitalization compared to low-intensity or no statin use (adjusted HR 0.31, p=0.0014).
  • This association persisted even in patients with controlled LDL cholesterol and in those without incident coronary artery disease events.

Conclusions:

  • Moderate-intensity statins are associated with a reduced incidence of heart failure in patients with type 2 diabetes.
  • The cardioprotective effect of moderate-intensity statins against HF in this population is independent of low-density lipoprotein (LDL) cholesterol levels and coronary artery disease events.
Abstract

Keywords:
Cardiovascular Disease RiskCholesterolCoronary Artery DiseaseHeart Failure

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
585
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
419
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K